The Use of Molecular Analyses in Voided Urine for the Assessment of Patients with Hematuria

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Beukers, Willemien ^a   Kandimalla, Raju ^a   van Houwelingen, Diandra ^a   Kovacic, Hrvoje ^a   Chin, Jie Fen D ^a   Lingsma, Hester F ^a   Dyrskjot, Lars ^b   Zwarthoff, Ellen C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BLADDER CANCER; BOOTSTRAPPING; CANCER GRADING; CONTROLLED STUDY; CYSTOSCOPY; DNA METHYLATION; FEMALE; GENE; HEMATURIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MEIS1 GENE; ONECUT2 GENE; OSR1 GENE; OTX1 GENE; SENSITIVITY AND SPECIFICITY; SIM2 GENE; TRANSITIONAL CELL CARCINOMA; URINALYSIS; URINE CYTOLOGY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; FEMALE; HEMATURIA; HUMANS; MALE; METHYLATION; MIDDLE AGED; MODELS, STATISTICAL; MULTIVARIATE ANALYSIS; RISK ASSESSMENT; URINARY BLADDER NEOPLASMS; URINATION; YOUNG ADULT;

EID: 84885445768     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077657     Document Type: Article

References (17)

1. Mariani AJ, Mariani MC, Macchioni C, Stams UK, Hariharan A, et al. (1989) The significance of adult hematuria: 1,000 hematuria evaluations including a risk-benefit and cost-effectiveness analysis. J Urol 141: 350-355. PubMed: 2492350.
2. Cohen RA, Brown RS, (2003) Clinical practice. Microscopic hematuria. N Engl J Med 348: 2330-2338. doi:10.1056/NEJMcp012694. PubMed: 12788998.
3. Khadra MH, Pickard RS, Charlton M, Powell PH, Neal DE, (2000) A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice. J Urol 163: 524-527. doi:10.1016/S0022-5347(05)67916-5. PubMed: 10647670.
4. Jocham D, Witjes F, Wagner S, Zeylemaker B, van Moorselaar J, et al. (2005) Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol 174: 862-866; discussion: 10.1097/01.ju.0000169257.19841.2a. PubMed: 16093971.
5. Witjes JA, Douglass J, (2007) The role of hexaminolevulinate fluorescence cystoscopy in bladder cancer. Nat Clin Pract Urol 4: 542-549. doi:10.1038/ncpgasthep0921. PubMed: 17921969.
6. Kandimalla R, Masius RB, W, Bangma CH, Orntoft TF, Dyrskjot L, et al. (2013) A 3-plex methylation assay for sensitive detection of recurrent bladder cancer in voided urine. Clin Cancer Res 19: 4760-4769. doi:10.1158/1078-0432.CCR-12-3276. PubMed: 23842048.
7. Shariat SF, Sfakianos JP, Droller MJ, Karakiewicz PI, Meryn S, et al. (2010) The effect of age and gender on bladder cancer: a critical review of the literature. BJU Int 105: 300-308. doi:10.1111/j.1464-410X.2009.09076.x. PubMed: 19912200.
8. Lotan Y, Capitanio U, Shariat SF, Hutterer GC, Karakiewicz PI, (2009) Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection. BJU Int 103: 1368-1374. doi:10.1111/j.1464-410X.2009.08360.x. PubMed: 19338566.
9. Summerton N, Mann S, Rigby AS, Ashley J, Palmer S, et al. (2002) Patients with new onset haematuria: assessing the discriminant value of clinical information in relation to urological malignancies. Br J Gen Pract 52: 284-289. PubMed: 11942444.
10. O'Sullivan P, Sharples K, Dalphin M, Davidson P, Gilling P, et al. (2012) A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria. J Urol 188: 741-747. doi:10.1016/j.juro.2012.05.003. PubMed: 22818138.
11. Sarosdy MF, Kahn PR, Ziffer MD, Love WR, Barkin J, et al. (2006) Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria. J Urol 176: 44-47. doi:10.1016/S0022-5347(06)00576-3. PubMed: 16753364.
12. Schmitz-Dräger BJ, Beiche B, Tirsar LA, Schmitz-Dräger C, Bismarck E, et al. (2007) Immunocytology in the assessment of patients with asymptomatic microhaematuria. Eur Urol 51: 1582-1588; discussion: 10.1016/j.eururo.2006.10.046. PubMed: 17107748.
13. Roobol MJ, Bangma CH, el Bouazzaoui S, Franken-Raab CG, Zwarthoff EC, (2010) Feasibility study of screening for bladder cancer with urinary molecular markers (the BLU-P project). Urol Oncol 28: 686-690. doi:10.1016/j.urolonc.2009.12.002. PubMed: 21062653.
14. Abogunrin F, O'Kane HF, Ruddock MW, Stevenson M, Reid CN, et al. (2012) The impact of biomarkers in multivariate algorithms for bladder cancer diagnosis in patients with hematuria. Cancer 118: 2641-2650. doi:10.1002/cncr.26544. PubMed: 21918968.
15. Cha EK, Tirsar LA, Schwentner C, Christos PJ, Mian C, et al. (2012) Immunocytology is a strong predictor of bladder cancer presence in patients with painless hematuria: a multicentre study. Eur Urol 61: 185-192. doi:10.1016/j.eururo.2011.08.073. PubMed: 21924544.
16. Karakiewicz PI, Benayoun S, Zippe C, Lüdecke G, Boman H, et al. (2006) Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. BJU Int 97: 997-1001. doi:10.1111/j.1464-410X.2006.06036.x. PubMed: 16542342.
17. Steyerberg EW, Harrell FE Jr., Borsboom GJ, Eijkemans MJ, Vergouwe Y, et al. (2001) Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol 54: 774-781. doi:10.1016/S0895-4356(01)00341-9. PubMed: 11470385.